Genolier Swiss Medical Network (GSMN): Swiss Takeover Board examines acting in concert in connection with declaration of participations

Genolier Swiss Medical Network (GSMN) / Miscellaneous/Miscellaneous

28.06.2010 07:17

Dissemination of a Adhoc News, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.


Within its duty to ensure compliance with the rules applicable to public
takeover offers (art. 23. para. 3 Federal Act on Stock Exchanges and
Securities Trading), the Swiss Takeover Board has submitted to Genolier
Swiss Medical Network SA a number of questions in connection with the
notification of the constitution of a group by Lincoln Vale European
Partners Master Fund L.P., Alain Fabarez and Jaime Rosell, which was
published on 14 June 2010.

The company currently has no indication for the existence of a group that
would be subject to an obligation to make a public takeover offer.

About Genolier Swiss Medical Network SA
Genolier Swiss Medical Network SA is a major private hospital network in
Switzerland, listed on the main segment of the Swiss Stock Exchange SIX
(GSMN:SW). The group's growth strategy focuses on the development of a
national hospital network through the acquisition of clinics and the
integration of their operations. GSMN's main goal is to provide top-quality
hospital care to Swiss and foreign patients. GSMN manages six private
hospitals in Switzerland: Clinique de Genolier, Clinique de Montchoisi,
Clinique Valmont, Clinique Générale, Centre medico-chirurgical des
Eaux-Vives and Privatklinik Bethanien. The total number of beds of the six
clinics is 501. The group employs 1072 staff members. In 2009 GSMN reported
revenues of CHF 139m, an EBITDA of CHF 8.8m and a Net Profit of CHF 1.9m.

For further information please contact : 
Sacha Wigdorovits
Contract Media AG
T +41 44 209 60 00
M +41 79 404 17 05

28.06.2010 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at and

This website uses cookies.
Please see our Privacy Guidelines for further details.